Eli Lilly

News

Lilly partners with Sidekick in digital health alliance

A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge from a newly-announced partnership between digital health specialist Sidekick an

News

Lilly's Olumiant okayed in alopecia, with Pfizer, Concert in...

Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,

News

Sanofi's plans for OTC Cialis hit a snag in US

It has been eight years since Sanofi licensed rights to an over-the-counter version of erectile dysfunction (ED) drug Cialis from Eli Lilly, and the FDA has just thrown a spanner into its p

News

Lilly sets aside $2.1bn for domestic investments

Eli Lilly's home state of Indiana is set to benefit from a massive $2.1 billion investment by the pharma group, earmarked for two brand new manufacturing facilities.

News

Second trial opens door for Lilly's mirikizumab in ulcerativ...

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory review

News

CHMP backs Sanofi's Xenpozyme as first drug for ASMD

Sanofi's Genzyme unit has moved a step closer to securing EU approval for Xenpozyme – its enzyme replacement therapy for rare disease acid sphingomyelinase deficiency (ASMD) – after scoring

Lilly partners with Sidekick in digital health alliance

Lilly's Olumiant okayed in alopecia, with Pfizer, Concert in...

Sanofi's plans for OTC Cialis hit a snag in US

Lilly sets aside $2.1bn for domestic investments

Second trial opens door for Lilly's mirikizumab in ulcerativ...

CHMP backs Sanofi's Xenpozyme as first drug for ASMD

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks